Ivonescimab (AK112) 是一种 PD-1/VEGF 双特异性抗体。Ivonescimab 可用于癌症研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-PD-1 & VEGF Reference Antibody (Ivonescimab) is 201.13 kDa.

Anti-PD-1 & VEGF Reference Antibody (Ivonescimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-PD-1 & VEGF Reference Antibody (Ivonescimab)is 98.33%, determined by SEC-HPLC.

Ivonescimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Ivonescimab bound to huPD-1-His, and the EC50 was 0.051 nM.

Ivonescimab bound to VEGFA protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Ivonescimab bound to huVEGFA-His, and the EC50 was 0.021 nM.

Ivonescimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Ivonescimab bound to huPD-1-Jurkat cells, and the EC50 was 6.274 nM.

Co-incubation of Ivonescimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Ivonescimab was able to block the PD-1/PD-L1 signaling pathway, and the EC50 was 7.957 nM.

Co-incubation of Ivonescimab with VEGF protein, then with the addition of VEGF-NF-AT-HEK293 cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Ivonescimab can neutralize VEGF-165, and the IC50 was 7.957 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.